This article is more than 5 years old. Information may no longer be current.

Lucentis approved in Switzerland

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BASEL, Switzerland — The Swiss Agency for Therapeutic Products has granted Novartis Ophthalmics marketing approval for its drug ranibizumab, the company announced.

This is the first European approval for Lucentis (ranibizumab, Novartis) as a treatment for exudative age-related macular degeneration, according to a press release from Novartis.

Lucentis, which is marketed in the United States by Genentech, received U.S. Food and Drug Administration approval in June. Novartis retains exclusive rights to commercialize the drug in the rest of the world and has applied for marketing approval in the European Union and Australia, according to the release.